SciELO - Scientific Electronic Library Online

vol.19 número1Procalcitonina como predictor temprano de bacteriemia en pacientes neutropénicos críticamente enfermosNeumonitis asociada al tratamiento con paclitaxel índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados




Links relacionados

  • No hay artículos similaresSimilares en SciELO


Gaceta mexicana de oncología

versión On-line ISSN 2565-005Xversión impresa ISSN 1665-9201


QUINTANA-QUINTANA, Miguel et al. Perspectives on the use of tyrosine kinase inhibitors in thyroid cancer. Gac. mex. oncol. [online]. 2020, vol.19, n.1, pp.24-32.  Epub 30-Abr-2021. ISSN 2565-005X.


Thyroid cancer has generally a good prognosis after surgical and/or radioactive iodine (RAI) treatment; however, these tumors that persist or that are not candidate to these treatments have a worse prognosis, which makes the use of tyrosine kinase inhibitors (TKIs) a good management alternative, since it has demonstrated progression-free survival (PFS) and response rate benefits, and it is, therefore, important to describe new markers and future therapies for this type of tumors.

Materials and methods:

The purpose of this review is to describe the current state of the treatment of advanced or relapsing thyroid cancer that is not susceptible to management with surgery or RAI, the benefits, and limitations of the use of TKIs, as well as an analysis of this tumor’s molecular biology and its clinical repercussion.


The use of sorafenib and lenvatinib in differentiated thyroid carcinoma that is refractory to RAI, and cabozantinib and vandetanib for advanced medullary carcinomas, has demonstrated benefit in this type of patients, with an impact on PFS, response rates, and disease control. There are ongoing studies with immunotherapy, and we will be alert for their results.


The treatment with TKI in metastatic thyroid cancer, has shown benefit, the determination of mutations and markers will determine which is the best TKI for the different subtypes of thyroid cancer.

Palabras llave : Thyroid cancer; Tyrosine kinase inhibitors; Treatment.

        · resumen en Español     · texto en Inglés     · Inglés ( pdf )